Drugs / LBT-3627
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06466525 | Jul 2024 → Oct 2025 overdue | Parkinson disease | Longevity Biotech Australia Pty Ltd (subsidiary) | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-12-16 | Longevity Biotech Australia Pty Ltd (subsidiary) | Results Pioneering Neuroprotective Results Achieved in Parkinson’s Disease Preclinical Studies longevitybiotech.com ↗
The key finding in our study was that a specific white blood cell subset was produced as a consequence of LBT-3627 treatment and provided protection of dopamine producing nerve cells from being damaged. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBT-3627 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06466525 ↗ |
| Modality | Peptide | “Synthetic peptide” NCT06466525 ↗ |